Article
Hematology
Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J. Deyell, Jamie E. Flerlage, Anna K. Franklin, Jennifer Krajewski, Kasey J. Leger, Lianna J. Marks, Robin E. Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul D. Harker-Murray, Lisa Giulino-Roth
Summary: Through a retrospective analysis of 67 pediatric patients, it was found that brentuximab vedotin in combination with vedotin had good tolerability and a safety profile similar to that of adult patients in the treatment of relapsed/refractory Hodgkin lymphoma. With a median follow-up of 37 months, the 3-year progression-free survival was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in children with relapsed/refractory Hodgkin lymphoma.
Article
Oncology
Weiping Liu, Meng Wu, Yan Xie, Chen Zhang, Lingyan Ping, Feier Feng, Xin Leng, Lan Mi, Xiaopei Wang, Jun Zhu, Yuqin Song
Summary: Lymphoma patients undergoing AHSCT with inadequate HSC doses had longer time to neutrophil and platelet engraftment, but overall survival rates were not significantly different compared to patients with unfavorable HSC doses.
LEUKEMIA & LYMPHOMA
(2021)
Editorial Material
Hematology
Peter W. M. Johnson
Summary: The study shows that treating relapsed or refractory HL with PD-1 antibody nivolumab has a high response rate, making it an attractive option for second-line therapy.
Article
Hematology
Filomena Emanuela Laddaga, Pierluigi Masciopinto, Claudia Nardelli, Margherita Patrizia Vacca, Paola Masciandaro, Elena Arcuti, Ettore Cicinelli, Giorgina Specchia, Pellegrino Musto, Francesco Gaudio
Summary: In recent years, there has been a significant improvement in the prognosis of patients with Hodgkin lymphoma (HL). However, the study found that HL and its treatment can have an impact on the fertility of male patients, with hematopoietic stem cell transplantation (HSCT) associated with severe impairment of sperm motility. First-line treatment, on the other hand, showed a statistically significant improvement in fertility in terms of motility for HL patients who did not undergo HSCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Oncology
Yazeed Samara, Matthew Mei
Summary: Standard second-line therapy for relapsed and/or refractory Hodgkin lymphoma patients includes salvage therapy and autologous stem cell transplantation. However, the introduction of novel agents and treatment strategies has changed patients' decision-making and pre-transplant treatment, as well as post-transplant maintenance therapy.
Article
Hematology
Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muff Ly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen -Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai
Summary: The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has significantly changed over the past decade with the use of brentuximab vedotin (BV) and PD-1 inhibitors. A study comparing outcomes from 2011 to 2020 with those from 2001 to 2010 showed improved overall survival (OS) and increased postprogression survival in the modern era, attributed to the use of BV and PD-1 inhibitors. Factors associated with inferior progression-free survival (PFS) included age ≥45 years, primary refractory disease, and lack of complete remission pre-AHCT, while receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS.
Article
Oncology
Chen Zhang, Jili Deng, Yan Xie, Lan Mi, Weiping Liu, Xiaopei Wang, Linjun Zhao, Yuqin Song, Jun Zhu
Summary: This study evaluated the outcomes of single or tandem ASCT in patients with refractory or relapsed classical Hodgkin lymphoma (R/R cHL), especially in high-risk patients. The results showed that tandem transplantation can significantly improve the progression-free survival rate in high-risk patients, but there was no significant difference in overall survival rate.
Article
Hematology
T. Brezina, H. von Dewitz, T. Schroeder, S. Ullrich, K. Nachtkamp, G. Reifenberger, B. Malzkorn, M. Sabel, R. Haas, G. Kobbe
Summary: This study retrospectively collected follow-up data from 61 patients with PCNS-NHL and found that treatment with high-dose therapy and autologous stem cell transplantation resulted in better overall response rate, progression-free survival, and overall survival compared to conventional chemoimmunotherapy alone.
ANNALS OF HEMATOLOGY
(2022)
Article
Hematology
Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio Chavez, Yago Nieto, Justin M. Darrah, Uttam Rao, Michael T. Byrne, David A. Bond, Kami J. Maddocks, Michael A. Spinner, Ranjana H. Advani, Hatcher J. Ballard, Jakub Svoboda, Anurag K. Singh, Joseph P. McGuirk, Dipenkumar Modi, Radhakrishnan Ramchandren, Jason Romancik, Jonathon B. Cohen, Matthew J. Frigault, Yi-Bin Chen, Anthony Serritella, Justine Kline, Stephen Ansell, Sunita Nathan, Maryam Rahimian, Robin M. Joyce, Mansi Shah, Kevin A. David, Steven Park, Anne W. Beaven, Alma Habib, Veronika Bachanova, Shazia Nakhoda, Nadia Khan, Ryan C. Lynch, Stephen D. Smith, Vincent T. Ho, Ann LaCasce, Philippe Armand, Alex F. Herrera
Summary: Autologous stem cell transplantation (ASCT) following anti-PD-1 therapy shows promising outcomes for relapsed/refractory Hodgkin lymphoma (HL) patients, even in high-risk cases, with favorable survival rates observed.
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Oncology
Ginevra Lolli, Beatrice Casadei, Vittorio Stefoni, Lisa Argnani, Francesca Bonifazi, Pier Luigi Zinzani
Summary: Hepatosplenic T-cell lymphoma is a challenging lymphoma to treat, but tandem consolidation therapy with auto-stem cell transplant and allo-stem cell transplant may induce a lasting response and potential cure.
Article
Obstetrics & Gynecology
Francesco Pallotti, Marianna Pelloni, Fabiana Faja, Silvia Di Chiano, Alice Di Rocco, Andrea Lenzi, Francesco Lombardo, Donatella Paoli
Summary: Most NHL patients have normal sperm quality before treatment, but salvage therapy followed by stem cell transplant can cause permanent damage to sperm production, resulting in 66% of long-term azoospermic patients.
HUMAN REPRODUCTION
(2021)
Article
Oncology
Nancy L. Bartlett
Summary: The Oncology Grand Rounds series aims to help readers apply key research findings to clinical practice through case studies, literature reviews, and treatment summaries, allowing for better understanding and application.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Julie M. Vose, Siddhartha Ganguly, Philip J. Bierman, R. Gregory Bociek, Matthew Lunning, Liz Lyden, Jane L. Meza, Paolo F. Caimi, James O. Armitage
Summary: Improved maintenance treatments are needed for patients with relapsed/refractory aggressive lymphomas after autologous haematopoietic stem cell transplantation (ASCT). Several studies have shown the activity of lenalidomide in treating relapsed/refractory aggressive lymphomas. However, the results of this study do not support the use of lenalidomide maintenance in this setting.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Rene-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Herve Ghesquieres, Aspasia Stamatoullas, Jehan Dupuis, Anne-Claire Gac, Thomas Gastinne, Bertrand Joly, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Franck Morschhauser, David Sibon, Christophe Bonnet, Alina Berriolo-Riedinger, Veronique Edeline, Marie Parrens, Diane Damotte, Diane Coso, Marc Andre, Michel Meignan, Cedric Rossi
Summary: The AHL2011 study showed that a PET-driven de-escalation strategy after two cycles of BEACOPP is as effective and safe as standard treatment for advanced Hodgkin lymphoma. Extended follow-up data confirmed the non-inferiority of the PET-driven strategy and the prognostic value of PET4 for identifying high-risk patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Hira S. Mian, Mark A. Fiala, Tanya M. Wildes
Summary: The study utilized a database to explore the treatment burden among newly diagnosed multiple myeloma patients, finding a significant burden in the first year, particularly within the first three months. Factors such as high comorbidities, poor performance status, and bone disease were associated with higher treatment burden.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2021)
Article
Oncology
Kah Poh Loh, Maya Abdallah, Sindhuja Kadambi, Megan Wells, Anita J. Kumar, Jason H. Mendler, Jane L. Liesveld, Marsha Wittink, Kristen O'Dwyer, Michael W. Becker, Colin McHugh, Wendy Stock, Navneet S. Majhail, Tanya M. Wildes, Paul Duberstein, Supriya Gupta Mohile, Heidi D. Klepin
Summary: Treatment decision-making in older patients with AML is influenced by patient-related factors such as comorbidities, functional status, emotional health, cognition, and social factors. Many patients perceive treatment as their only option and feel they have not been offered a choice.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Hira S. Mian, Hsien Seow, Tanya M. Wildes, C. Tom Kouroukis, Gregory R. Pond, Branavan Sivapathasundaram, Jonathan Sussman
Summary: The study identified disparities in treatment patterns and outcomes for older adults with newly diagnosed multiple myeloma. While rates of no treatment decreased over the study period, they remained high among older patients. Early mortality also varied between older and younger patients, with different trends in mortality rates depending on the treatment received. While improvements have been made, concerns remain regarding the rates of no treatment and early mortality among older adults with multiple myeloma.
JOURNAL OF GERIATRIC ONCOLOGY
(2021)
Editorial Material
Hematology
Sonja Zweegman, Tanya M. Wildes
Summary: This study demonstrates that modifying standard myeloma treatment based on frailty levels benefits elderly patients with newly diagnosed multiple myeloma by reducing toxicity while maintaining efficacy.
Letter
Oncology
Lawrence Liu, Mark Fiala, Feng Gao, Justin King, Scott Goldsmith, Tanya M. Wildes, Keith Stockerl-Goldstein, Ravi Vij, Mark A. Schroeder
Summary: The study found that 2nd-line DPd has a high efficacy in standard risk myeloma but lower efficacy in high risk myeloma, suggesting a need for further investigation.
LEUKEMIA & LYMPHOMA
(2021)
Editorial Material
Oncology
Hira Mian, Rinku Sutradhar, Gregory R. Pond, Branavan Sivapathasundaram, Jonathan Sussman, Amaris Balitsky, Anita D'Souza, Tanya M. Wildes, Hsien Seow
BLOOD CANCER JOURNAL
(2022)
Letter
Oncology
Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, J. Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter Voorhees
BLOOD CANCER JOURNAL
(2022)
Article
Medicine, General & Internal
Marielle Jensen-Battaglia, Lianlian Lei, Huiwen Xu, Lee Kehoe, Amita Patil, Kah Poh Loh, Erika Ramsdale, Allison Magnuson, Amber S. Kleckner, Tanya M. Wildes, Po-Ju Lin, Karen M. Mustian, Gilbert Giri, Mary Whitehead, James Bearden, Brian L. Burnette, Jodi Geer, Supriya G. Mohile, Richard F. Dunne
Summary: The functional status and physical performance of older adults with cancer are often overlooked and not properly addressed. This study examined the impact of providing oncologists with a geriatric assessment (GA) summary and recommendations on conversations about functional and physical performance with patients. The results showed that providing oncologists with a GA summary led to an increase in the proportion of patients having conversations about functional and physical performance and receiving relevant recommendations.
Editorial Material
Oncology
Stephanie L. Graff, Tanya Wildes, Narjust Duma, Don S. Dizon, Noelle K. LoConte, Edith Mitchell, Martina C. Murphy, Edith A. Perez, Sarah M. Temkin, Pamela L. Kunz, Karen M. Winkfield
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Katherine Clifton, Feng Gao, JoAnn Jabbari, Mary Van Aman, Patricia Dulle, Janice Hanson, Tanya M. Wildes
Summary: The COVID-19 pandemic has impacted the mental health of older adults, especially those with cancer. A study on older adults undergoing active cancer treatment during the pandemic found relatively low rates of loneliness and social isolation, but high rates of social support. Loneliness was positively correlated with social isolation and negatively correlated with social support and emotional support. There was no significant association between loneliness and markers of geriatric impairments.
JOURNAL OF GERIATRIC ONCOLOGY
(2022)
Article
Oncology
Mina S. Sedrak, Can-Lan Sun, Jingran Ji, Harvey J. Cohen, Cary P. Gross, William P. Tew, Heidi D. Klepin, Tanya M. Wildes, Efrat Dotan, Rachel A. Freedman, Tracey O'Connor, Selina Chow, Mary Ann Fenton, Beverly Moy, Andrew E. Chapman, William Dale, Vani Katheria, Nicole M. Kuderer, Gary H. Lyman, Allison Magnuson, Hyman B. Muss
Summary: Older women with high-risk early breast cancer often suffer from toxic side effects during adjuvant chemotherapy, leading to dose reductions and delays. Identifying women at risk of receiving suboptimal dose intensity may improve treatment discussions and guide early supportive care interventions.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Shakira J. Grant, Matthew Jansen, Tzy-Mey Kuo, Samuel M. Rubinstein, Tanya M. Wildes, Sascha A. Tuchman, Hyman B. Muss, Eben I. Lichtman, Marjory Charlot
Summary: Residents of communities facing social vulnerability have limited access to clinical trials, which leads to poor health outcomes. This study examined the association between social vulnerability and the availability of multiple myeloma trials in North Carolina. The results showed that counties with low poverty rates had more trial sites, while counties with the lowest percentage of Black Indigenous Persons of Color populations had fewer trial sites. Therefore, multilevel efforts are needed to improve the availability and access to trials for socially vulnerable populations.
JCO ONCOLOGY PRACTICE
(2023)
Review
Oncology
Sarah A. Holstein, Shakira J. Grant, Tanya M. Wildes
Summary: CAR T-cell and BsAb therapies have shown significant advancements in the treatment of multiple myeloma, but challenges remain in terms of safety considerations, optimal sequencing, supportive care measures, and equitable access across different racial, ethnic, and socioeconomic populations.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Hematology
Shakira J. Grant, Alyssa A. Grimshaw, Juliet Silberstein, Donna Murdaugh, Tanya M. Wildes, Ashley E. Rosko, Smith Giri
Summary: CAR-T cell therapy is a novel treatment for patients with relapsed or refractory hematologic malignancies, often leading to symptoms of ICANS. Studies have found that the clinical presentation, onset, severity, and acute or long-term outcomes of ICANS vary.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Geriatrics & Gerontology
Arielle Elkrief, Cassandra Hennessy, Nicole M. Kuderer, Samuel M. Rubinstein, Elizabeth Wulff-Burchfield, Rachel P. Rosovsky, Karen Vega-Luna, Michael A. Thompson, Orestis A. Panagiotou, Aakash Desai, Donna R. Rivera, Ali Raza Khaki, Lisa Tachiki, Ryan C. Lynch, Catherine Stratton, Rawad Elias, Gerald Batist, Anup Kasi, Dimpy P. Shah, Ziad Bakouny, Angelo Cabal, Jessica Clement, Jennifer Crowell, Becky Dixon, Christopher R. Friese, Stacy L. Fry, Punita Grover, Shuchi Gulati, Shilpa Gupta, Clara Hwang, Hina Khan, Soo Jung Kim, Elizabeth J. Klein, Chris Labaki, Rana R. McKay, Amanda Nizam, Nathan A. Pennell, Matthew Puc, Andrew L. Schmidt, Armin Shahrokni, Justin A. Shaya, Christopher T. Su, Sarah Wall, Nicole Williams, Trisha M. Wise-Draper, Sanjay Mishra, Petros Grivas, Benjamin French, Jeremy L. Warner, Tanya M. Wildes
Summary: This study aims to quantify the association of a novel geriatric risk index with COVID-19 severity and 30-day mortality among older adults with cancer. The results show a strong association between the geriatric risk index and COVID-19 severity and mortality, providing clinicians with a risk stratification method to identify high-risk older adults.
LANCET HEALTHY LONGEVITY
(2022)